{"id":"basal-bolus-insulin-therapy","safety":{"commonSideEffects":[{"rate":"variable, depends on glycemic targets and patient adherence","effect":"Hypoglycemia"},{"rate":"common","effect":"Weight gain"},{"rate":"5-10","effect":"Injection site reactions"},{"rate":"rare to uncommon","effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL1201631","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This regimen mimics physiological insulin secretion by combining a steady background (basal) insulin level with meal-time (bolus) insulin injections. The basal component suppresses hepatic glucose production between meals and overnight, while bolus doses control postprandial glucose spikes. Both components work by binding to insulin receptors on muscle and adipose tissue to promote glucose uptake and utilization.","oneSentence":"Basal bolus insulin therapy replaces the body's natural insulin secretion by providing a long-acting basal insulin dose once or twice daily plus rapid-acting bolus insulin doses with meals to control blood glucose.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:42:57.166Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus (when other agents insufficient)"}]},"trialDetails":[{"nctId":"NCT06762314","phase":"PHASE2","title":"Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes","status":"RECRUITING","sponsor":"Mostafa Bahaa","startDate":"2025-01-20","conditions":"Diabetes","enrollment":105},{"nctId":"NCT04416269","phase":"PHASE4","title":"Oral Anti Diabetic Agents in the Hospital","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2020-08-07","conditions":"Diabetes Mellitus","enrollment":255},{"nctId":"NCT05785832","phase":"NA","title":"A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tandem Diabetes Care, Inc.","startDate":"2023-06-01","conditions":"Type 2 Diabetes Treated With Insulin","enrollment":319},{"nctId":"NCT06334068","phase":"NA","title":"SHOrt-term Glycemic Control for Reducing Post-SURGical Complications","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2024-05-08","conditions":"Diabetes, Uncontrolled Diabtetes","enrollment":53},{"nctId":"NCT07282639","phase":"NA","title":"App-Based Certified Diabetes Education Therapy (AB-CDE)","status":"NOT_YET_RECRUITING","sponsor":"Oregon Health and Science University","startDate":"2026-01-15","conditions":"Type 1 Diabetes (T1D)","enrollment":99},{"nctId":"NCT05305794","phase":"PHASE3","title":"Effect of Weekly GLP1 Agonist Treatment in \"Double Diabetes\"","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2022-07-12","conditions":"Double Diabetes","enrollment":76},{"nctId":"NCT04016558","phase":"NA","title":"Behavioral Approaches to Reducing Diabetes Distress and Improving Glycemic Control","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2019-09-15","conditions":"Type 1 Diabetes, Diabetes Distress","enrollment":296},{"nctId":"NCT06420518","phase":"","title":"Accuracy of a Continuous Ketone Monitoring (CKM) System in Individuals With Type 1 Diabetes on Insulin Pump Therapy.","status":"COMPLETED","sponsor":"McGill University","startDate":"2024-04-30","conditions":"type1diabetes","enrollment":16},{"nctId":"NCT06627517","phase":"NA","title":"Safety and Effectiveness of the Luna System in People With Type 1 Diabetes Mellitus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Luna Diabetes","startDate":"2024-11-22","conditions":"Type 1 Diabetes Mellitus, Sleep Quality","enrollment":120},{"nctId":"NCT07066891","phase":"NA","title":"Validation of Insulin Dose Prediction Model Based on Artificial Intelligence Algorithm","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-07-15","conditions":"Diabetes Mellitus, Type 2 Diabetes","enrollment":400},{"nctId":"NCT06605859","phase":"","title":"DigiDiab Pilot Spain - Nursing Home and Domiciliary Nursing Care","status":"RECRUITING","sponsor":"Medical University of Graz","startDate":"2025-04-08","conditions":"Type 2 Diabetes","enrollment":40},{"nctId":"NCT06616779","phase":"","title":"DigiDiab Evaluation Domiciliary Nursing Care","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2024-11-30","conditions":"Type 2 Diabetes, Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes, Insulin Requiring","enrollment":40},{"nctId":"NCT06406439","phase":"NA","title":"DIA:CONN P8(Smart Insulin Pen) Study in Diabetes Patients","status":"COMPLETED","sponsor":"G2e Co., Ltd","startDate":"2024-05-21","conditions":"Diabetes (Insulin-requiring, Type 1 or Type 2), Pancreatogenic Diabetes Mellitus","enrollment":120},{"nctId":"NCT06738849","phase":"NA","title":"EkiYou-Study-2 : A National Multicentric Trial of the EkiYou Application for Insulin Bolus Calculation","status":"RECRUITING","sponsor":"DiappyMed","startDate":"2024-11-05","conditions":"Diabetes Type 1, Diabetes Type 2 on Insulin, Pancreatogenous Diabetes","enrollment":154},{"nctId":"NCT07004153","phase":"NA","title":"A Study of DIA:CONN P8 Smart Insulin Pen With CGM-Based Coaching in Patients With Type 1 or Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"G2e Co., Ltd","startDate":"2025-06","conditions":"Diabetes Mellitus","enrollment":152},{"nctId":"NCT06962410","phase":"NA","title":"Hybrid Closed-Loop in Diabetes Post-Kidney Transplant: A Randomized Trial","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-04-01","conditions":"Diabetes Mellitus Patients With Kidney Transplantation","enrollment":30},{"nctId":"NCT06909071","phase":"NA","title":"Hybrid Closed-Loop System in Neurosurgical Perioperative Hyperglycemia: An Open RCT","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-04-15","conditions":"T2DM Patients With Traumatic Brain Injury","enrollment":40},{"nctId":"NCT04617795","phase":"NA","title":"Omnipod® 5 Automated Insulin Delivery System in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Insulet Corporation","startDate":"2020-11-23","conditions":"Type 2 Diabetes Mellitus","enrollment":25},{"nctId":"NCT06855615","phase":"PHASE4","title":"Comparison of Thrice-Daily Premixed Human Insulin with Basal-Bolus Therapy Among Patients with Poorly Controlled Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Hospital Sultanah Aminah Johor Bahru","startDate":"2020-10-01","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":44},{"nctId":"NCT02542631","phase":"NA","title":"Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Calibra Medical, Inc.","startDate":"2015-08-01","conditions":"Diabetes Mellitus, Type 2","enrollment":278},{"nctId":"NCT06638567","phase":"NA","title":"Postoperative Basal Bolus or Sliding Scale Insulin Regimen in DM2 and Its Effect on Surgical Site Infections.","status":"RECRUITING","sponsor":"Abraham Hulst, MD, PhD","startDate":"2025-01-03","conditions":"Diabetes Mellitus, Type 2, Surgical Site Infection","enrollment":1008},{"nctId":"NCT03087032","phase":"PHASE4","title":"Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2019-01-10","conditions":"Type 2 Diabetes Patients, Overweight and Obesity, Hyperglycaemia (Diabetic)","enrollment":164},{"nctId":"NCT05768191","phase":"PHASE4","title":"Comparative Efficacy of a Two Daily Mixed Insulin Injection Versus a Basal-bolus Scheme With Human Insulin","status":"COMPLETED","sponsor":"Université NAZI BONI","startDate":"2023-06-15","conditions":"Type 1 Diabetes","enrollment":22},{"nctId":"NCT05036876","phase":"NA","title":"Degludec Glargine U300 Hospital Study","status":"COMPLETED","sponsor":"Medanta, The Medicity, India","startDate":"2021-10-10","conditions":"Type 2 Diabetes","enrollment":220},{"nctId":"NCT06487598","phase":"NA","title":"To Evaluate add-on Effect of Nisha-Amalaki Tablets Along With Insulin on Glycemic Control in Type 1 Diabetes Patients (RCTNA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hirabai Cowasji Jehangir Medical Research Institute","startDate":"2024-07-01","conditions":"Type 1 Diabetes","enrollment":70},{"nctId":"NCT06600776","phase":"PHASE4","title":"Mealtime or Post-meal Dosing of URLi in Medtronic 780G Hybrid Closed Loop System","status":"NOT_YET_RECRUITING","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2024-10-06","conditions":"Type 1 Diabetes (T1D)","enrollment":50},{"nctId":"NCT06607224","phase":"NA","title":"Effect of the Use of Continuous Glucose Monitoring Versus Standard Glycemic Control in Hospitalized Patients with Type 2 Diabetes.","status":"COMPLETED","sponsor":"Hospital General Universitario Gregorio Marañon","startDate":"2022-01-10","conditions":"Diabetes Mellitus Type 2, Hospitalization","enrollment":40},{"nctId":"NCT05118945","phase":"","title":"Study on the Use of the Insulin Pump Tandem X:2 With Control IQ Algorithm - Update","status":"COMPLETED","sponsor":"Kinderkrankenhaus auf der Bult","startDate":"2021-03-03","conditions":"Type 1 Diabetes, Insulin Therapy","enrollment":50},{"nctId":"NCT02558491","phase":"NA","title":"Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM","status":"COMPLETED","sponsor":"Daniel Chernavvsky, MD","startDate":"2015-09","conditions":"Type 1 Diabetes Mellitus","enrollment":33},{"nctId":"NCT04123054","phase":"NA","title":"A Novel mHealth Application Guided by an Optimization Algorithm for T1D Sensor-Augmented Insulin Injection Users","status":"COMPLETED","sponsor":"McGill University","startDate":"2020-03-05","conditions":"Diabetes Mellitus, Diabetes Mellitus, Type 1","enrollment":84},{"nctId":"NCT06046417","phase":"PHASE2, PHASE3","title":"A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2023-11-30","conditions":"type1diabetes, Diabetes Mellitus, Type 1","enrollment":30},{"nctId":"NCT06297980","phase":"NA","title":"Impact of MEnstruation on Glycemic Response and Exercise In Females With Type 1 Diabetes","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2024-03-15","conditions":"Type 1 Diabetes, Hypoglycemia, Hyperglycaemia Due to Type 1 Diabetes Mellitus","enrollment":150},{"nctId":"NCT05360537","phase":"PHASE4","title":"Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients","status":"COMPLETED","sponsor":"University of Palermo","startDate":"2021-04-01","conditions":"Diabetes Mellitus, Type 2","enrollment":100},{"nctId":"NCT04019821","phase":"PHASE4","title":"Super-Bolus: Effects on Postprandial Glycemia After High Glycemic Index Meal","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2020-01-01","conditions":"Diabetes Mellitus, Type 1","enrollment":72},{"nctId":"NCT00313742","phase":"PHASE4","title":"The Effect of Exercise on Blood Glucose Levels in Patients With Type 1 Diabetes: A Comparison of 3 Long-acting Insulins","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-04","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":51},{"nctId":"NCT05067270","phase":"PHASE1","title":"A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-10-22","conditions":"Type 1 Diabetes Mellitus","enrollment":40},{"nctId":"NCT06057077","phase":"PHASE1, PHASE2","title":"Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolus","status":"UNKNOWN","sponsor":"Ministry of Health, Saudi Arabia","startDate":"2024-01-01","conditions":"Type 1 Diabetes","enrollment":120},{"nctId":"NCT00357890","phase":"NA","title":"Insulin Pump Therapy in Adolescents With Newly Diagnosed Type 1 Diabetes (T1D)","status":"COMPLETED","sponsor":"Nemours Children's Clinic","startDate":"2005-12","conditions":"Diabetes Mellitus, Insulin-Dependent","enrollment":12},{"nctId":"NCT00788840","phase":"PHASE4","title":"Detemir Energy Expenditure Study","status":"COMPLETED","sponsor":"University of Surrey","startDate":"2008-01","conditions":"Type 2 Diabetes Mellitus, Obesity","enrollment":30},{"nctId":"NCT03387787","phase":"PHASE2, PHASE3","title":"Evaluation of Glycaemic Control Using GlucoTab® With Insulin Degludec in Hospitalized Patients With Diabetes Mellitus Type 2","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2018-01-30","conditions":"Type 2 Diabetes Mellitus","enrollment":15},{"nctId":"NCT04871958","phase":"NA","title":"Individualized, Technological Interventions for Diabetes Care in the COVID-19 Ward","status":"TERMINATED","sponsor":"Federico II University","startDate":"2021-03-19","conditions":"Diabetes Mellitus, Covid19","enrollment":66},{"nctId":"NCT03557892","phase":"NA","title":"Sensor-augmented Pump Versus Multiple Daily Injections With Degludec as Basal Insulin for Insulin Therapy in Type 1 Diabetes","status":"COMPLETED","sponsor":"Azienda Ospedaliero-Universitaria Careggi","startDate":"2018-04-01","conditions":"Diabetes Mellitus, Type 1","enrollment":28},{"nctId":"NCT04726163","phase":"NA","title":"Tele-expertise in Patients With Diabetes Hospitalized for Covid-19 Infection","status":"TERMINATED","sponsor":"University Hospital, Strasbourg, France","startDate":"2021-01-29","conditions":"Diabetic Patient (Type 1,2, MODY, Secondary) or With Corticosteroid-induced Diabetes Following Initiation of Corticosteroid Treatment","enrollment":48},{"nctId":"NCT03436498","phase":"PHASE1","title":"Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion for Type 1 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-05-10","conditions":"Type 1 Diabetes Mellitus","enrollment":45},{"nctId":"NCT03406000","phase":"PHASE4","title":"Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U/mL","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-01-22","conditions":"Type I Diabetes Mellitus","enrollment":170},{"nctId":"NCT02194595","phase":"PHASE3","title":"Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)","status":"COMPLETED","sponsor":"Mount Sinai Hospital, Canada","startDate":"2014-09","conditions":"Type 2 Diabetes","enrollment":105},{"nctId":"NCT03895515","phase":"","title":"Effect of Fiasp® in Type 1 Diabetes Treatment","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-01-03","conditions":"Diabetes Mellitus, Type 1","enrollment":178},{"nctId":"NCT03547427","phase":"NA","title":"Glucagon Counterregulation in Type 1 Diabetes","status":"TERMINATED","sponsor":"University of Virginia","startDate":"2018-05-20","conditions":"Type 1 Diabetes Mellitus","enrollment":13},{"nctId":"NCT04847778","phase":"NA","title":"Assess the Impact of Insulclock on Glycemic Variability and Treatment Compliance in Uncontrolled DM1 Patients","status":"COMPLETED","sponsor":"Hospital General de Segovia","startDate":"2021-03-01","conditions":"Diabetes Mellitus, Type 1","enrollment":80},{"nctId":"NCT00591227","phase":"PHASE4","title":"Management of Diabetes in the Emergency Room: a Randomized Trial of an Insulin Protocol.","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2008-05","conditions":"Type 2 Diabetes Mellitus","enrollment":176},{"nctId":"NCT05152121","phase":"NA","title":"Additional Insulin for High Fat/Protein in Type 1 Diabetes","status":"COMPLETED","sponsor":"Ege University","startDate":"2017-07-01","conditions":"Type 1 Diabetes, Adolescent","enrollment":20},{"nctId":"NCT04323462","phase":"PHASE4","title":"Intensive Glycemic Control For Diabetic Foot Ulcer Healing","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2021-10-01","conditions":"Diabetic Foot Ulcer","enrollment":326},{"nctId":"NCT01512654","phase":"NA","title":"Personalized Glucose Predictive and Therapy Advisory System - DIAdvisor 2","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2008-09","conditions":"Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1","enrollment":60},{"nctId":"NCT03670641","phase":"PHASE4","title":"Remission Through Early Monitored Insulin Therapy - Duration Month","status":"COMPLETED","sponsor":"Sandra Sobel","startDate":"2019-03-26","conditions":"Type 2 Diabetes Mellitus","enrollment":10},{"nctId":"NCT04542213","phase":"PHASE3","title":"Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19","status":"COMPLETED","sponsor":"Hospital Regional de Alta Especialidad del Bajio","startDate":"2020-08-01","conditions":"Hyperglycemia, Covid19","enrollment":70},{"nctId":"NCT01484457","phase":"EARLY_PHASE1","title":"Controlled Insulin Delivery: Combining Technology With Treatment","status":"COMPLETED","sponsor":"Sansum Diabetes Research Institute","startDate":"2008-07","conditions":"Diabetes Mellitus, Type 1","enrollment":19},{"nctId":"NCT04409587","phase":"PHASE4","title":"Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump","status":"COMPLETED","sponsor":"Mountain Diabetes and Endocrine Center","startDate":"2018-04-12","conditions":"Type1 Diabetes Mellitus","enrollment":59},{"nctId":"NCT04739241","phase":"PHASE4","title":"Premixed vs Basal Bolus Insulin Therapy in Older Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Consorci Sanitari Integral","startDate":"2014-01-24","conditions":"Type 2 Diabetes Treated With Insulin","enrollment":60},{"nctId":"NCT02229227","phase":"PHASE3","title":"Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-11-21","conditions":"Diabetes Mellitus, Type 2","enrollment":814},{"nctId":"NCT04414579","phase":"PHASE4","title":"The Efficacy and Safety of Faster Insulin Aspart (Fiasp®) Compared to Conventional Insulin Aspart (NovoLog®) as Correction Bolus","status":"UNKNOWN","sponsor":"Mountain Diabetes and Endocrine Center","startDate":"2019-03-27","conditions":"Type 1 Diabetes Mellitus","enrollment":45},{"nctId":"NCT01957930","phase":"NA","title":"Intensive Insulin Treatment and Ischemic Foot Ulcer","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"1984-01","conditions":"Ischemic Foot Ulcer","enrollment":91},{"nctId":"NCT03862690","phase":"","title":"A Research Study, Looking at How NovoMix® Works in People With Type 2 Diabetes in Local Clinical Practice in Algeria","status":"WITHDRAWN","sponsor":"Novo Nordisk A/S","startDate":"2020-05-28","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT02284009","phase":"PHASE2","title":"Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-10-10","conditions":"Diabetes Mellitus, Type 1","enrollment":67},{"nctId":"NCT04226378","phase":"","title":"Canadian Real-World Outcomes of Omnipod Initiation in People With T1D","status":"COMPLETED","sponsor":"LMC Diabetes & Endocrinology Ltd.","startDate":"2020-01-20","conditions":"Diabetes Mellitus, Type 1","enrollment":286},{"nctId":"NCT02965443","phase":"PHASE4","title":"Dapagliflozin + Saxagliptin in a Basal-bolus Insulin Treatment","status":"TERMINATED","sponsor":"University Hospital Tuebingen","startDate":"2018-02-02","conditions":"Type 2 Diabetes","enrollment":4},{"nctId":"NCT01170208","phase":"NA","title":"Insulin Dosage Software Program for People With Type 1 and Type 2 Diabetes","status":"COMPLETED","sponsor":"HealthPartners Institute","startDate":"2010-06","conditions":"Diabetes, Insulin","enrollment":46},{"nctId":"NCT00564018","phase":"NA","title":"Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH","status":"TERMINATED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2006-09","conditions":"Type 1 Diabetes","enrollment":33},{"nctId":"NCT03764280","phase":"NA","title":"The Efficacy of MDI Treatment With an Optimization Algorithm Adjusting Basal-Bolus Parameters in Children and Adolescents With Type 1 Diabetes at a Diabetes Camp","status":"COMPLETED","sponsor":"McGill University","startDate":"2018-07-02","conditions":"Diabete Mellitus, Diabetes Mellitus, Type 1","enrollment":21},{"nctId":"NCT02192450","phase":"PHASE4","title":"Insulin Degludec and Symptomatic Nocturnal Hypoglycaemia","status":"COMPLETED","sponsor":"Nordsjaellands Hospital","startDate":"2015-01","conditions":"Type 1 Diabetes Mellitus, Nocturnal Hypoglycemia, Recurrent Severe Hypoglycaemia","enrollment":149},{"nctId":"NCT02455076","phase":"PHASE4","title":"Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Emory University","startDate":"2015-09","conditions":"Type 2 Diabetes","enrollment":150},{"nctId":"NCT01850615","phase":"PHASE3","title":"Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-09-23","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":323},{"nctId":"NCT03970668","phase":"","title":"Linagliptin in Post-renal Transplantation","status":"COMPLETED","sponsor":"Universidad de Guanajuato","startDate":"2016-01-01","conditions":"Transplanted Kidney Complication","enrollment":28},{"nctId":"NCT01868594","phase":"PHASE4","title":"Clinical Trial of Efficacy and Safety of Subetta in the Combined Treatment of Patients With Type I Diabetes Mellitus","status":"COMPLETED","sponsor":"Materia Medica Holding","startDate":"2013-05-07","conditions":"Type I Diabetes Mellitus","enrollment":200},{"nctId":"NCT02152384","phase":"PHASE1","title":"A Study to Compare and Measure the Effects of Insulin Peglispro (LY2605541) and Glargine on Meal Time Insulin Requirements","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-06","conditions":"Diabetes Mellitus, Type 1","enrollment":28},{"nctId":"NCT02004366","phase":"PHASE4","title":"Linagliptin Inpatient Trial","status":"COMPLETED","sponsor":"Emory University","startDate":"2014-01","conditions":"Type 2 Diabetes","enrollment":295},{"nctId":"NCT03838783","phase":"PHASE4","title":"Flexible Insulin Therapy Untethered Insulin Regimen in Avidly Exercising Patients With Type 1 Diabetes: FIT Untethered","status":"UNKNOWN","sponsor":"LMC Diabetes & Endocrinology Ltd.","startDate":"2018-05-15","conditions":"Type 1 Diabetes Mellitus","enrollment":30},{"nctId":"NCT02453685","phase":"PHASE4","title":"A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-08-31","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":335},{"nctId":"NCT01819129","phase":"PHASE3","title":"Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-09-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":881},{"nctId":"NCT00979628","phase":"PHASE4","title":"Basal Bolus Versus Basal Insulin in Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Guillermo Umpierrez, MD","startDate":"2010-01","conditions":"Type 2 Diabetes, Hyperglycemia","enrollment":375},{"nctId":"NCT01792830","phase":"PHASE3","title":"Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients","status":"COMPLETED","sponsor":"Emory University","startDate":"2012-10","conditions":"Poor Glycemic Control","enrollment":175},{"nctId":"NCT00945659","phase":"NA","title":"Use of Continuous Glucose Sensors by Adolescents With Inadequate Diabetic Control","status":"COMPLETED","sponsor":"Nemours Children's Clinic","startDate":"2009-08","conditions":"Type 1 Diabetes Mellitus","enrollment":116},{"nctId":"NCT03554590","phase":"NA","title":"DM1, Effects of Carbo-Counting on Glycemic Control","status":"UNKNOWN","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2016-12","conditions":"Type 1 Diabetes Mellitus","enrollment":50},{"nctId":"NCT02012465","phase":"EARLY_PHASE1","title":"Validation of Insulin Protocol for Glucocorticoid-induced Hyperglycemia in Diabetic Oncology Patients","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2013-09","conditions":"Lymphoma, Diabetes Mellitus, Type 2, Hyperglycemia","enrollment":15},{"nctId":"NCT03335501","phase":"PHASE2","title":"Comparison of the Efficacy of Rapid-acting Aspart and Faster Acting Aspart Within the Context of Single-hormone Closed-loop Strategy at Regulating Postprandial Glucose Levels","status":"WITHDRAWN","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2018-04-01","conditions":"Type 1 Diabetes Mellitus","enrollment":""},{"nctId":"NCT01662921","phase":"PHASE2","title":"Comparator Trial Using Insulin Glulisine vs. Insulin Lispro for Treatment of Gestational Diabetes","status":"COMPLETED","sponsor":"Sansum Diabetes Research Institute","startDate":"2013-04","conditions":"Diabetes During Pregnancy","enrollment":17},{"nctId":"NCT02420262","phase":"PHASE3","title":"A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-07-26","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":506},{"nctId":"NCT03463564","phase":"PHASE4","title":"Insulin Pump vs Multiple Daily Injections of Insulin and Glyco-metabolic Control in Type 1 Diabetic Patients","status":"RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2016-01","conditions":"Type 1 Diabetes Mellitus","enrollment":150},{"nctId":"NCT01182493","phase":"NA","title":"OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy","status":"COMPLETED","sponsor":"Medtronic Diabetes","startDate":"2010-12","conditions":"Diabetes Mellitus, Type 2","enrollment":331},{"nctId":"NCT01594060","phase":"PHASE4","title":"Basal Bolus vs. Sliding Scale for Treatment of Diabetic Patients in Medical Wards","status":"COMPLETED","sponsor":"HaEmek Medical Center, Israel","startDate":"2012-06","conditions":"Diabetes Mellitus Type 2","enrollment":36},{"nctId":"NCT01572740","phase":"PHASE3","title":"Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-04-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":257},{"nctId":"NCT02490098","phase":"PHASE2","title":"Closed-loop Control of Postprandial Glucose Levels in Children and Adults With Type 1 Diabetes","status":"WITHDRAWN","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2018-01","conditions":"Type 1 Diabetes","enrollment":""},{"nctId":"NCT00922649","phase":"NA","title":"Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes","status":"COMPLETED","sponsor":"Animas Corporation","startDate":"2008-02-01","conditions":"Type 2 Diabetes","enrollment":58},{"nctId":"NCT03051243","phase":"PHASE3","title":"Safety and Efficiency of Linagliptin (Trajenta) in the Setting of Internal Medicine Department","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2017-10-01","conditions":"DM2","enrollment":60},{"nctId":"NCT03244241","phase":"PHASE4","title":"Basal-bolus Insulin Therapy Versus Standard Therapy for the Inpatient Management of Type 2 Diabetes: the IDA2 Study","status":"UNKNOWN","sponsor":"Merete Bechmann Christensen","startDate":"2017-04-01","conditions":"Type 2 Diabetes Mellitus","enrollment":100},{"nctId":"NCT01945138","phase":"NA","title":"Closed Loop Insulin Pump Therapy After Islet Auto-Transplantation","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2014-02","conditions":"Chronic Pancreatitis, Diabetes Mellitus","enrollment":14},{"nctId":"NCT02182895","phase":"PHASE4","title":"Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2014-07","conditions":"Diabetes Mellitus","enrollment":72},{"nctId":"NCT01845831","phase":"PHASE4","title":"Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Emory University","startDate":"2013-08","conditions":"Type 2 Diabetes","enrollment":292},{"nctId":"NCT03112538","phase":"PHASE4","title":"Improving Glycaemic Control in Malaysian Patients With Type 2 Diabetes Mellitus With Insulin Pump Therapy","status":"UNKNOWN","sponsor":"Clinical Research Centre, Malaysia","startDate":"2016-01","conditions":"Type 2 Diabetes Mellitus","enrollment":118},{"nctId":"NCT00972283","phase":"PHASE3","title":"Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-09-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1006},{"nctId":"NCT01814137","phase":"PHASE3","title":"A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":188,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"basal bolus insulin therapy","genericName":"basal bolus insulin therapy","companyName":"Consorci Sanitari Integral","companyId":"consorci-sanitari-integral","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Basal bolus insulin therapy replaces the body's natural insulin secretion by providing a long-acting basal insulin dose once or twice daily plus rapid-acting bolus insulin doses with meals to control blood glucose. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus (when other agents insufficient).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}